Artificial Intelligence in COPD is transforming disease management, from underdiagnosis to treatment guidance. Discover how machine learning clusters patients, predicts outcomes, and optimizes healthcare resources.
Discover the first study designed to analyze the impact of EVLP on the lung microbiome and the local inflammatory response. Understanding the composition, diversity, and functional interactions of the pulmonary microbiome in lung transplants holds promise for personalized respiratory medicine.
Explore Treatable Traits model for chronic airway diseases like asthma and COPD in primary care. Learn about seven key traits — airflow obstruction, eosinophilic inflammation, adherence, inhaler technique, smoking, low BMI/obesity and anxiety and depression — that guide personalized care.
Explore the complex pathophysiology of bronchiectasis, including airway infection, chronic inflammation, and mucociliary dysfunction. Learn how genomic approaches, proteomics, and epigenomics offer new insights into disease endotypes and patient stratification for improved therapies. Discover the role of trained innate immunity in complementing current models.
Explore how the treatable traits approach can be applied to pre-COPD, potentially preventing full disease development. Learn about GETomics and its role in understanding pre-COPD through gene-environment interactions.
La TM (telemedicina) podría ayudar en el tratamiento de la EPOC, pero aún queda un largo camino para poder implantar un sistema seguro a nivel nacional.
Some patients develop post-COVID organizing pneumonia (OP), which is responsiveto treatment with corticosteroids.
The efficacy and safety of mepolizumab in patients with COPD has been investigated in two placebo-controlled Phase 3 trials, METREX and METREO, and theongoing MATINEE trial.
Treatment with LABA/LAMA is recommended in GOLD B patients. We hypothesized that triple therapy (LABA/LAMA/ICS) will be superior to LABA/LAMA in achieving and maintaining clinical control
The prevalence and diagnostic utility of bronchodilator responsiveness (BDR) in a real-life setting is unclear. Objective: To explore this uncertainty
